ApconiX are experts in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.
ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company founded on the skills and experience of a growing team with a wide range of expertise in nonclinical drug safety.
The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners. There are many more SMEs and academic groups who also need access to specialised services.
ApconiX addresses all needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way. In this way, companies work with people they trust, to make better decisions on drug safety.